A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-18

Study Completion Date

2026-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415

Amount of NKTR-118 in Blood Variation in the Heart's Electrical Cycle

COMPLETED PHASE1

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

NCT06107036

Healthy

COMPLETED PHASE1

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

NCT06310876

Healthy

COMPLETED PHASE1

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

NCT05878522

Healthy

COMPLETED PHASE1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

NCT02228707

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MK-1167

MK-1167 administered orally

Group Type EXPERIMENTAL

MK-1167

Intervention Type DRUG

Oral capsule administered once daily

Placebo

Placebo for MK-1167 administered orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral capsule administered once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-1167

Oral capsule administered once daily

Intervention Type DRUG

Placebo

Oral capsule administered once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is in good health
* Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive

* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
* Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes